Evidence map›Paper›PMID 35117856›Full record

ArticleTranslational cancer research2020

Development and validation of a nomogram for predicting the overall survival of patients with lung large cell neuroendocrine carcinoma.

Junjie Xi, Mengnan Zhao, Yuansheng Zheng, Jiaqi Liang, Zhengyang Hu, Yiwei Huang, Yong Yang, Cheng Zhan, Wei Jiang, Tao Lu and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Junjie Xi *Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Mengnan Zhao *Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuansheng Zheng *Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiaqi LiangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhengyang HuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yiwei HuangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yong YangDepartment of Thoracic Surgery, Suzhou Hospital affiliated to Nanjing Medical University, Suzhou, China.
Cheng ZhanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wei JiangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Tao LuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Weigang GuoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qun WangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNSun Yat-sen University · CNZhongshan Hospital · CNNanjing Medical University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung large cell neuroendocrine carcinoma (L-LCNEC) is a rare and rapidly progressing lung cancer. We aimed to formulate a nomogram model to predict the survival of L-LCNEC patients.

methodsClinical data of patients with L-LCNEC, lung large cell cancer (L-LCC) and small cell lung cancer (SCLC) were derived from the Surveillance, Epidemiology, and End Results (SEER) database. The characteristics and prognosis of L-LCNEC were investigated by comparing with that of L-LCC and SCLC, respectively. All L-LCNEC patients were randomly assigned into training group and validation group. A prognostic nomogram model was established for the overall survival (OS) in L-LCNEC patients. Furthermore, we enrolled 112 L-LCNEC patients from our department to validate the nomogram model.

result3,076 L-LCNEC, 11,163 L-LCC, and 78,097 SCLC patients were collected and enrolled in our analyses. Compared with L-LCC and SCLC, differences were observed in L-LCNEC in age, sex, race, marital status, SEER registry, TNM stage, and treatment. Furthermore, higher proportions of L-LCNEC were located at the upper lobe and unilateral lung compared with SCLC. L-LCNEC has similar survival to L-LCC, but better than SCLC. We identified that the age, gender, T, N, and M classification, and treatment were the independent prognostic predictors. A nomogram model was formulated to predict the OS. Calibration curves were performed to show optimal coherence between predicted probability of survival and actual survival, with a concordance index of 0.775. The external cohort included 112 patients and all of them underwent surgical treatment. The external validation demonstrated the reliability of this model.

conclusionsThe nomogram demonstrated its discrimination capability to predict the OS for L-LCNEC patients.

Indexed as

Lung large cell neuroendocrine carcinoma (L-LCNEC)nomogramSEER databasevalidation

Identifiers

PMID35117856
PMCPMC8799202
OpenAlexW3080925576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.